PARP Inhibitors for Cancer Therapy

Ken Y. Lin; W. Lee Kraus

doi:10.1016/j.cell.2017.03.034

PARP Inhibitors for Cancer Therapy

Ken Y. Lin, W. Lee Kraus

Research output: Contribution to journal › Short survey › peer-review

79 Scopus citations

Abstract

Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

Original language	English (US)
Pages (from-to)	183
Number of pages	1
Journal	Cell
Volume	169
Issue number	2
DOIs	https://doi.org/10.1016/j.cell.2017.03.034
State	Published - Apr 6 2017

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2017.03.034

Cite this

@article{695ad58b29e94134a65ae397b0fc3c10,

title = "PARP Inhibitors for Cancer Therapy",

abstract = "Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.",

author = "Lin, {Ken Y.} and Kraus, {W. Lee}",

note = "Publisher Copyright: {\textcopyright} 2017",

year = "2017",

month = apr,

day = "6",

doi = "10.1016/j.cell.2017.03.034",

language = "English (US)",

volume = "169",

pages = "183",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - PARP Inhibitors for Cancer Therapy

AU - Lin, Ken Y.

AU - Kraus, W. Lee

PY - 2017/4/6

Y1 - 2017/4/6

N2 - Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

AB - Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.

UR - http://www.scopus.com/inward/record.url?scp=85016957959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016957959&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.03.034

DO - 10.1016/j.cell.2017.03.034

M3 - Short survey

C2 - 28388401

AN - SCOPUS:85016957959

SN - 0092-8674

VL - 169

SP - 183

JO - Cell

JF - Cell

IS - 2

ER -

PARP Inhibitors for Cancer Therapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this